Summary by Moomoo AI
Sihuan Pharm Holdings Group Limited ("Sihuan Pharm") announced its financial report for the first half of 2024, showing total revenue of approximately RMB 949.7 million, a 10.0% year-on-year decrease. The loss for the period is approximately RMB 68.0 million, a 42.8% reduction from the same period last year. The company declared a mid-year dividend of RMB 0.19 per share, totaling approximately RMB 177,080,000. Sihuan Pharm's medical aesthetics product division performed strongly, with revenue increasing by 66.4% year-on-year, while the innovative drugs and other pharmaceutical divisions recorded losses. Additionally, the company repurchased 10,000,000 shares of its own stock as treasury shares through the exchange during the reporting period. There were no significant events after the reporting period.
